IVERMECTIN

The United States Food and Drug Administration (FDA) approved ivermectin on November 22, 1987.

Ivermectin is primarily an antiparasitic agent for treating several parasitic infections in humans and animals. Its approved uses include combating conditions such as onchocerciasis (river blindness), strongyloidiasis (threadworm infection), scabies, lice infestations, and lymphatic filariasis. This versatile medication's ability to target and disrupt the nervous systems of parasites makes it an essential tool in controlling and managing these parasitic diseases.

Ivermectin can be administered through oral tablets or liquid solutions, topical creams or lotions for skin applications, or injections for certain cases, depending on the formulation and treatment condition. Healthcare providers determine the appropriate route of administration based on the specific circumstances and type of parasitic infection. Always follow the recommended method and dosage as directed by a healthcare professional or indicated on the medication packaging.

Ivermectin use can lead to a range of side effects. Common side effects encompass gastrointestinal disturbances, skin reactions, fatigue, dizziness, muscle and joint pain, and changes in appetite. Serious side effects are rare but may include allergic reactions, neurological effects, eye-related symptoms, and potential liver impacts. Adhering to prescribed dosages, promptly reporting severe reactions, and consulting a healthcare provider is crucial to ensure safe and effective use of ivermectin.

Rarely, severe allergic reactions can occur, including rash, itching, swelling, dizziness, and difficulty breathing. Ivermectin may cause dizziness, drowsiness, tremors, and other neurological symptoms, especially at higher doses. Some individuals may experience changes in vision, including blurriness or double vision. The liver metabolizes it; in rare cases, it can cause liver-related issues, especially in individuals with pre-existing liver conditions. Itching, rash, redness, and skin irritation can occur, especially with topical applications. Some individuals may experience fatigue or weakness. Muscle or joint pain might occur. Some individuals might experience changes in appetite. Sleep disruption or sleepiness can occur in some cases. If not used as directed or if treatment is stopped prematurely, the parasites might not be eliminated, leading to treatment failure.

If you experience signs of an allergic reaction, such as rash, itching, swelling, or difficulty breathing, seek immediate medical attention. Avoid activities requiring full attention, such as driving or operating machinery, if you experience neurological effects. Individuals with pre-existing liver conditions should discuss their health with their healthcare provider before using Ivermectin. Take this medication with food if it is known to cause gastrointestinal discomfort. Follow the prescribed dosing schedule and complete the full course of treatment even if symptoms improve to ensure complete eradication of parasites. Always consult your healthcare provider for personalized guidance based on your health circumstances.

Seek medical advice before using this medicine, especially if you are pregnant, breastfeeding, have liver or kidney problems, or have a weakened immune system. Inform your healthcare provider about any allergies, current medications, and relevant medical conditions. Be mindful of possible drug interactions, including those involving alcohol, and use caution when driving or operating machinery if the medicine causes dizziness or drowsiness.

Report any severe or unusual reactions to your healthcare provider promptly. Take the medicine strictly according to the prescribed dose and complete the recommended course of treatment. For conditions such as scabies, maintain good personal hygiene and follow the recommended preventive measures. Use the medicine responsibly to help reduce the risk of drug resistance. Dosage adjustments may be necessary for children based on their age, weight, or medical condition.

Galderma (U.K) Ltd, Electronic medicines compendium (EMC), [Revised on 28 Nov 2022] [ Accessed on 8th August 2023], https://www.medicines.org.uk/emc/product/6819/smpc#gref Jennifer Keiser, James McCarthy, and Peter Hotez, Chemotherapy of Helminth Infections, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 2018, 1001-1009. US Food and Drug Administration, [Revised on March 16, 2023] [ Accessed on 08/08/2023] https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwivermectin4covidcom-650184-03162023#:~:text=FDA%2Dapproved%20ivermectin%20tablets%20are,are%20only%20available%20by%20prescription .